You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
|
|---|---|
| Published in |
Oncogene, January 2008
|
| DOI | 10.1038/sj.onc.1210911 |
| Pubmed ID | |
| Authors |
A M Krieg |
| Abstract |
Although still early in clinical development, agonists of Toll-like receptor 9 (TLR9) have demonstrated potential for the treatment of cancer. TLR9 agonists directly induce activation and maturation of plasmacytoid dendritic cells and enhance differentiation of B cells into antibody-secreting plasma cells. Preclinical and early clinical data support the use of TLR9 agonists in patients with solid tumors and hematologic malignancies. In preclinical studies, TLR9 agonists have shown activity not only as monotherapy, but also in combination with multiple other therapies, including vaccines, antibodies, cellular therapies, other immunotherapies, antiangiogenic agents, radiotherapy, cryotherapy and some chemotherapies. Phase I and II clinical trials have indicated that these agents have antitumor activity as single agents and enhance the development of antitumor T-cell responses when used as therapeutic vaccine adjuvants. The activity and safety of these novel anticancer agents are being explored in a wide range of tumor types as part of a variety of therapeutic strategies with the goal of harnessing the immune response to fight cancer. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 296 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 3 | 1% |
| Germany | 1 | <1% |
| Australia | 1 | <1% |
| Czechia | 1 | <1% |
| United Kingdom | 1 | <1% |
| Switzerland | 1 | <1% |
| Slovenia | 1 | <1% |
| Denmark | 1 | <1% |
| United States | 1 | <1% |
| Other | 1 | <1% |
| Unknown | 284 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 65 | 22% |
| Student > Ph. D. Student | 64 | 22% |
| Student > Bachelor | 33 | 11% |
| Student > Master | 27 | 9% |
| Student > Doctoral Student | 17 | 6% |
| Other | 35 | 12% |
| Unknown | 55 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 85 | 29% |
| Medicine and Dentistry | 38 | 13% |
| Biochemistry, Genetics and Molecular Biology | 36 | 12% |
| Immunology and Microbiology | 22 | 7% |
| Chemistry | 16 | 5% |
| Other | 34 | 11% |
| Unknown | 65 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 February 2023.
All research outputs
#2,148,848
of 23,410,748 outputs
Outputs from Oncogene
#503
of 10,760 outputs
Outputs of similar age
#8,224
of 158,734 outputs
Outputs of similar age from Oncogene
#3
of 59 outputs
Altmetric has tracked 23,410,748 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,760 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 158,734 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.